EXIQON ENTERS INTO A DEFINITIVE AGREEMENT TO ACCQUIRE ONCOTECH INC AND ENTERS THE MARKET FOR CANCER MOLECULAR DIAGNOSTICS Summary: Exiqon A/S (OMX: EXQ) has entered into a final and definitive agreement under which Exiqon will acquire California-based Oncotech Inc., a leading supplier of extreme drug resistance diagnostic tests in cancer. The merger of the two companies will create a world leader in molecular diagnostic products based on miRNA.
Exiqon A/S enters into a definitive agreement to acquire Oncotech, Inc. and enters the market for cancer molecular diagnostics
| Source: Exiqon A/S